Ministry of Health and Welfare announced this January that Bendamustine has been approved for NHI benefit, and is effective on February 1st . Bendamustine is approved to be used together with Roche's Polivy (polatuzumab vedotin) and MabThera (rituximab) to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have not received and are not suitable for hematopoietic stem cell transplantation.

All Bendamustine product license holders will benefit from this coverage. Based on estimated 1,750 DLBCL adult patients per year, Innopharmax expects that the annual sales volume of Innomustine® will increase by approximately 10-20%.